Lannett Company Company Profile (NYSE:LCI)

About Lannett Company (LCI)

Lannett Company logoLannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: LCI
  • CUSIP: 51601210
Key Metrics:
  • Previous Close: $21.45
  • 50 Day Moving Average: $21.73
  • 200 Day Moving Average: $23.35
  • 52-Week Range: $16.75 - $39.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 6.66
  • P/E Growth: 1.92
  • Market Cap: $797.70M
  • Outstanding Shares: 37,189,000
  • Beta: 2.24
  • Net Margins: -3.48%
  • Return on Equity: 21.95%
  • Return on Assets: 6.79%
  • Debt-to-Equity Ratio: 1.62%
  • Current Ratio: 2.00%
  • Quick Ratio: 1.61%

Analyst Ratings

Consensus Ratings for Lannett Company (NYSE:LCI) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $32.40 (51.05% upside)

Analysts' Ratings History for Lannett Company (NYSE:LCI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/2/2017Roth CapitalSet Price TargetBuy$28.00N/AView Rating Details
12/6/2016Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
10/18/2016Deutsche Bank AGReiterated RatingHold$32.00 -> $26.00N/AView Rating Details
8/24/2016Raymond James Financial, Inc.Boost Price TargetOutperform$31.00 -> $43.00N/AView Rating Details
3/25/2016Susquehanna Bancshares IncLower Price Target$37.00 -> $30.00N/AView Rating Details
3/25/2016Craig HallumLower Price TargetBuy$35.00N/AView Rating Details
3/24/2016Canaccord GenuityDowngradeBuy -> Sell$28.00 -> $18.00N/AView Rating Details
(Data available from 3/25/2015 forward)


Earnings History for Lannett Company (NYSE:LCI)
Earnings by Quarter for Lannett Company (NYSE:LCI)
Earnings History by Quarter for Lannett Company (NYSE:LCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2017Q217$0.84$0.92$169.04 million$171.00 millionViewListenView Earnings Details
11/3/2016Q117$0.71$0.77$166.72 million$161.60 millionViewN/AView Earnings Details
8/23/2016Q416$0.59$0.73$161.55 million$168.90 millionViewListenView Earnings Details
5/3/2016Q316$0.63$0.75$160.49 million$163.70 millionViewN/AView Earnings Details
2/3/2016Q216$0.94$0.95$141.62 million$127.06 millionViewN/AView Earnings Details
11/4/2015Q116$0.89$0.99$103.90 million$106.40 millionViewN/AView Earnings Details
8/25/2015Q415$0.86$0.91$99.30 millionViewListenView Earnings Details
5/6/2015Q315$0.94$0.97$101.10 million$99.40 millionViewN/AView Earnings Details
2/4/2015Q215$1.06$1.21$102.95 million$114.80 millionViewN/AView Earnings Details
11/3/2014Q115$0.79$0.94$91.40 million$93.40 millionViewN/AView Earnings Details
8/27/2014Q414$0.54$0.64$79.50 million$80.60 millionViewN/AView Earnings Details
5/7/2014Q314$0.60$0.63$84.50 million$80.00 millionViewN/AView Earnings Details
2/6/2014Q214$0.39$0.46$62.21 million$67.30 millionViewN/AView Earnings Details
11/7/2013Q114$0.13$0.22$41.14 million$45.82 millionViewN/AView Earnings Details
9/10/2013Q4 2013$0.07$0.12$37.89 million$40.20 millionViewN/AView Earnings Details
5/8/2013Q3 2013$0.13$0.14$35.14 million$39.00 millionViewN/AView Earnings Details
2/7/2013Q2 2013$0.05$0.10$33.53 million$36.60 millionViewN/AView Earnings Details
11/8/2012Q113$0.05$0.07$33.76 million$35.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Lannett Company (NYSE:LCI)
Current Year EPS Consensus Estimate: $3.44 EPS
Next Year EPS Consensus Estimate: $3.22 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$0.60$0.91$0.77
Q2 20167$0.62$1.10$0.93
Q4 20163$0.59$0.60$0.60
Q1 20173$0.65$0.73$0.69
Q2 20173$0.80$0.91$0.86
Q3 20173$0.82$0.93$0.89
Q4 20173$0.86$0.95$0.91
Q1 20181$0.68$0.68$0.68
Q2 20181$0.76$0.76$0.76
Q3 20181$0.72$0.72$0.72
Q4 20181$0.73$0.73$0.73
(Data provided by Zacks Investment Research)


Dividend History for Lannett Company (NYSE:LCI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Lannett Company (NYSE:LCI)
Insider Ownership Percentage: 15.04%
Institutional Ownership Percentage: 80.82%
Insider Trades by Quarter for Lannett Company (NYSE:LCI)
Institutional Ownership by Quarter for Lannett Company (NYSE:LCI)
Insider Trades by Quarter for Lannett Company (NYSE:LCI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/6/2017Arthur P BedrosianCEOBuy10,000$20.00$200,000.00View SEC Filing  
12/2/2016David FarberMajor ShareholderSell3,800$25.00$95,000.00View SEC Filing  
9/15/2016G. Michael LandisInsiderSell4,334$32.30$139,988.20View SEC Filing  
9/1/2016James M MaherDirectorSell1,478$33.91$50,118.98View SEC Filing  
8/31/2016G. Michael LandisInsiderSell6,786$33.41$226,720.26View SEC Filing  
6/23/2016Robert EhlingerVPSell37,141$25.06$930,753.46View SEC Filing  
6/20/2016Robert EhlingerVPSell62,859$25.40$1,596,618.60View SEC Filing  
3/1/2016Robert EhlingerVPSell69,247$25.41$1,759,566.27View SEC Filing  
2/5/2016Arthur P BedrosianCEOBuy4,500$24.91$112,095.00View SEC Filing  
2/5/2016David A DrabikDirectorBuy1,277$24.74$31,592.98View SEC Filing  
2/5/2016Kevin SmithVPBuy1,500$24.75$37,125.00View SEC Filing  
2/5/2016Martin P GalvanCFOBuy3,000$24.65$73,950.00View SEC Filing  
9/15/2015Arthur P BedrosianCEOSell5,000$55.64$278,200.00View SEC Filing  
9/8/2015John AbtVPBuy1,000$54.77$54,770.00View SEC Filing  
8/17/2015Arthur P BedrosianCEOSell5,000$52.81$264,050.00View SEC Filing  
7/15/2015Arthur P BedrosianCEOSell5,000$61.92$309,600.00View SEC Filing  
6/15/2015Arthur P BedrosianCEOSell5,000$56.31$281,550.00View SEC Filing  
5/15/2015Arthur P BedrosianCEOSell5,000$53.27$266,350.00View SEC Filing  
4/15/2015Arthur P BedrosianCEOSell5,000$69.43$347,150.00View SEC Filing  
3/16/2015Arthur P BedrosianCEOSell5,000$65.23$326,150.00View SEC Filing  
3/16/2015William SchreckCOOSell134,635$64.99$8,749,928.65View SEC Filing  
3/6/2015William SchreckCOOSell50,000$63.35$3,167,500.00View SEC Filing  
2/18/2015David A DrabikDirectorSell12,500$61.55$769,375.00View SEC Filing  
2/17/2015Arthur P BedrosianCEOSell5,000$59.89$299,450.00View SEC Filing  
2/17/2015G. Michael LandisInsiderSell11,500$58.60$673,900.00View SEC Filing  
2/13/2015Jeffrey FarberDirectorSell35,000$58.18$2,036,300.00View SEC Filing  
2/11/2015Kevin SmithVPSell109,436$56.51$6,184,228.36View SEC Filing  
2/9/2015David FarberMajor ShareholderSell2,500$55.00$137,500.00View SEC Filing  
2/9/2015Kevin SmithVPSell53,534$55.36$2,963,642.24View SEC Filing  
2/6/2015G. Michael LandisInsiderSell12,049$52.93$637,753.57View SEC Filing  
1/26/2015David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
1/15/2015Arthur P BedrosianCEOSell5,000$43.50$217,500.00View SEC Filing  
12/15/2014Arthur P BedrosianCEOSell5,000$43.81$219,050.00View SEC Filing  
12/10/2014Martin P GalvanCFOBuy1,000$42.40$42,400.00View SEC Filing  
12/8/2014Ernest SaboVPSell6,000$48.03$288,180.00View SEC Filing  
10/27/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
9/16/2014Arthur P BedrosianCEOSell5,000$40.05$200,250.00View SEC Filing  
8/18/2014David FarberMajor ShareholderSell5,000$41.30$206,500.00View SEC Filing  
7/15/2014Arthur P BedrosianCEOSell5,000$47.19$235,950.00View SEC Filing  
6/23/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
6/16/2014Arthur P BedrosianCEOSell5,000$46.96$234,800.00View SEC Filing  
6/16/2014David FarberMajor ShareholderSell10,000$43.53$435,300.00View SEC Filing  
6/16/2014Paul TaveiraDirectorSell1,000$46.94$46,940.00View SEC Filing  
3/17/2014William SchreckCOOSell16,600$43.85$727,910.00View SEC Filing  
3/12/2014William SchreckCOOSell55,563$43.31$2,406,433.53View SEC Filing  
2/20/2014Kevin SmithVPSell64,665$45.11$2,917,038.15View SEC Filing  
2/13/2014Kevin SmithVPSell20,000$40.48$809,600.00View SEC Filing  
12/13/2013Arthur BedrosianCEOBuy5,000$27.85$139,250.00View SEC Filing  
12/13/2013Martin GalvanCFOBuy3,000$26.90$80,700.00View SEC Filing  
5/14/2013Kevin SmithVPSell24,984$11.86$296,310.24View SEC Filing  
5/13/2013Kevin SmithVPSell41,929$11.80$494,762.20View SEC Filing  
5/10/2013Ernest SaboVPSell15,000$11.29$169,350.00View SEC Filing  
3/14/2013Paul TaveiraDirectorBuy1,000$9.73$9,730.00View SEC Filing  
2/13/2013Martin P GalvanCFOBuy4,000$6.88$27,520.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Lannett Company (NYSE:LCI)
Latest Headlines for Lannett Company (NYSE:LCI)
DateHeadline logoZacks Investment Research Downgrades Lannett Company, Inc. (LCI) to Hold - March 24 at 1:41 PM logoLannett Company (LCI) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow - March 22 at 11:28 PM logoIs Lannett (LCI) a Great Stock for Value Investors? - March 21 at 12:03 PM logoHow These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Lannett, Rigel Pharma, and Catalent - PR Newswire (press release) - March 17 at 6:28 PM logoLannett To Participate At Four Upcoming Investor Conferences - February 27 at 6:21 PM logoLannett Announces Addition To Management Team - PR Newswire - PR Newswire (press release) - February 23 at 11:14 PM logoLannett Announces Addition To Management Team - February 23 at 6:13 PM logoLannett (LCI) Says FDA Suspended Deadline for Materials in Support of Hearing for Methylphenidate ER ANDA - February 22 at 12:18 PM logoFDA axes deadline for Lannett to submit supporting documents for generic version of ADHD med Concerta - February 22 at 12:18 PM logoLannett Provides Further Update On Methylphenidate ER Tablets - February 22 at 12:18 PM logo6:59 am Lannett notified that the FDA suspended indefinitely the deadline for the co to submit materials in support of its request for a hearing to consider FDA's proposal that the co withdraw its ANDA for Methylphenidate ER - February 22 at 12:18 PM logoFDA gives Lannett more time to make its case for ADHD drug - February 22 at 12:18 PM logoWill Lannett (LCI) Continue to Surge Higher? - February 16 at 4:58 PM logoCEO Buys Shares of Lannett - February 8 at 7:01 PM logoLannett completes extraction of ERP system from Kremers Urban - February 7 at 7:32 PM logoLannett Announces Successful Completion Of ERP System Extraction - February 7 at 7:32 PM logoAcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3% - February 6 at 10:13 AM logoAffimed (AFMD) Shows Strength: Stock Moves 8.1% Higher - February 6 at 10:13 AM logoStrong Earnings Numbers Ramp Up Pressure For Possible Lannett Short Squeeze - Benzinga - February 3 at 6:55 PM logoStrong Earnings Numbers Ramp Up Pressure For Possible Lannett Short Squeeze - February 2 at 6:58 PM logo4:23 pm Lannett beats by $0.08, beats on revs; reaffirms FY17 rev guidance - February 2 at 6:58 PM logoEdited Transcript of LCI earnings conference call or presentation 1-Feb-17 9:30pm GMT - February 2 at 5:06 AM logoLannett Company's (LCI) CEO Arthur Bedrosian on Q2 2017 Results - Earnings Call Transcript - February 2 at 12:05 AM logoQ2 2017 Lannett Company Inc Earnings Release - After Market Close - February 1 at 7:03 PM logoLannett Reports Fiscal 2017 Second-Quarter Financial Results - February 1 at 7:03 PM logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Lannett Company, Inc. -LCI - PR Newswire (press release) - January 26 at 8:03 PM logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Lannett Company, Inc. -LCI - January 26 at 12:40 AM logoLannett To Report Fiscal 2017 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 1 - January 25 at 7:38 PM logoLANNETT CO INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders - January 25 at 7:38 PM logoRobbins Arroyo LLP: Lannett Company, Inc. (LCI) Misled Shareholders According to a Recently Filed Class Action - January 23 at 6:34 PM logoLannett Voluntarily Pays Down $75 Million Of Revolving Credit Facility - January 23 at 10:31 AM logoLANNETT CO INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - January 19 at 8:03 PM


Frequently Asked Questions for Lannett Company (NYSE:LCI)

What is Lannett Company's stock symbol?

Lannett Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How were Lannett Company's earnings last quarter?

Lannett Company, Inc. (NYSE:LCI) issued its earnings results on Wednesday, February, 1st. The company reported $0.92 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.84 by $0.08. The firm earned $171 million during the quarter, compared to analysts' expectations of $169.04 million. Lannett Company had a negative net margin of 3.48% and a positive return on equity of 21.95%. The firm's revenue for the quarter was up 34.5% compared to the same quarter last year. During the same period last year, the firm posted $0.95 earnings per share.

When will Lannett Company make its next earnings announcement?

Lannett Company is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What guidance has Lannett Company issued on next quarter's earnings?

Lannett Company updated its second quarter earnings guidance on Tuesday, January, 26th. The company provided earnings per share guidance of $0.93-0.95 for the period, compared to the Thomson Reuters consensus estimate of $0.99. The company issued revenue guidance of $127 billion, compared to the consensus revenue estimate of $141.62 million.

Where is Lannett Company's stock going? Where will Lannett Company's stock price be in 2017?

5 brokers have issued 12 month price targets for Lannett Company's shares. Their predictions range from $26.00 to $43.00. On average, they expect Lannett Company's stock price to reach $32.40 in the next twelve months.

Who owns Lannett Company stock?

Lannett Company's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Deerfield Management Co. (5.40%), State Street Corp (3.22%), Dimensional Fund Advisors LP (2.63%), Thompson Siegel & Walmsley LLC (2.42%), Russell Investments Group Ltd. (1.16%) and Norges Bank (1.13%). Company insiders that own Lannett Company stock include Arthur P Bedrosian, David A Drabik, David Farber, G Michael Landis, James M Maher, John Abt, Kevin Smith, Martin P Galvan and Robert Ehlinger.

Who sold Lannett Company stock? Who is selling Lannett Company stock?

Lannett Company's stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Numeric Investors LLC, Pinnacle Associates Ltd., State Board of Administration of Florida Retirement System, Cantab Capital Partners LLP, Tudor Investment Corp Et Al and New York State Teachers Retirement System. Company insiders that have sold Lannett Company stock in the last year include David Farber, G Michael Landis, James M Maher and Robert Ehlinger.

Who bought Lannett Company stock? Who is buying Lannett Company stock?

Lannett Company's stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Co., Russell Investments Group Ltd., Norges Bank, FMR LLC, Thompson Siegel & Walmsley LLC, State Street Corp, Oxford Asset Management and Westwood Holdings Group Inc.. Company insiders that have bought Lannett Company stock in the last two years include Arthur P Bedrosian, David A Drabik, John Abt, Kevin Smith and Martin P Galvan.

How do I buy Lannett Company stock?

Shares of Lannett Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Lannett Company stock cost?

One share of Lannett Company stock can currently be purchased for approximately $21.45.

Lannett Company (LCI) Chart for Saturday, March, 25, 2017

This page was last updated on 3/25/2017 by Staff